Research graph
References from Lung squamous cell carcinoma complicated with immune checkpoint inhibitor-associated active tuberculosis: a case report and literature review. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
10.1056/nejmoa1606774 · 2016 · External reference
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
10.1016/j.ejca.2015.11.016 · 2016 · External reference
The paradox of immune checkpoint inhibition re-activating tuberculosis
10.1183/13993003.02512-2021 · 2022 · External reference
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
10.1038/ni1443 · 2007 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review
10.1007/s00262-020-02726-1 · 2021 · External reference
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial
10.1016/j.ccell.2024.05.024 · 2024 · External reference
Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma
10.3109/0284186x.2015.1125017 · 2016 · External reference
Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis
10.1016/j.jtho.2016.07.006 · 2016 · External reference
Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma
10.1016/j.jtho.2017.03.012 · 2017 · External reference
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents
10.1016/j.jiac.2018.06.016 · 2019 · External reference
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
10.1186/s40425-019-0717-7 · 2019 · External reference
Tuberculosis following PD-1 blockade for cancer immunotherapy
10.1126/scitranslmed.aat2702 · 2019 · External reference
Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: a case report
10.1111/1759-7714.13821 · 2021 · External reference
Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report
10.2217/imt-2020-0061 · 2020 · External reference
Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
10.1186/s12879-021-06845-7 · 2021 · External reference
Readministration of pembrolizumab after treatment of tuberculosis activated by initial pembrolizumab therapy
10.2169/internalmedicine.6002-20 · 2021 · External reference
Complete remission after immunotherapy-induced abdominal tuberculosis in a patient with advanced NSCLC treated with pembrolizumab: a case report
10.1016/j.jtocrr.2022.100319 · 2022 · External reference
Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report
10.2147/ott.s178246 · 2018 · External reference
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer
10.1080/0284186x.2018.1433877 · 2018 · External reference
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
10.1016/j.cmi.2017.12.003 · 2018 · External reference
A rare case of miliary tuberculosis in a patient with NSCLC receiving PD1 inhibitor therapy, mimicking autoimmune pneumonitis
10.4103/jcrt.jcrt_410_22 · 2023 · External reference
Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment
10.1093/qjmed/hcy243 · 2019 · External reference
Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review
10.3389/fonc.2019.00659 · 2019 · External reference
Implications of tuberculosis reactivation after immune checkpoint inhibition
10.1164/rccm.201807-1250le · 2018 · External reference
Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review
10.3389/fimmu.2023.1162190 · 2023 · External reference
Significant neutrophilic emperipolesis in squamous cell carcinoma
10.1155/2018/1301562 · 2018 · External reference
A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment
10.21037/cco-23-153 · 2024 · External reference
Pulmonary reversed halo cycles and consolidations after immunotherapy: a case report
10.12998/wjcc.v11.i28.6938 · 2023 · External reference
The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis
10.1016/j.tube.2016.10.001 · 2016 · External reference
PD-1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis
10.1038/srep38362 · 2016 · External reference
The blockade of immune checkpoints in cancer immunotherapy
10.1038/nrc3239 · 2012 · External reference
T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection
10.1371/journal.pone.0019864 · 2011 · External reference
CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease
10.1371/journal.ppat.1005667 · 2016 · External reference
Prednisone for prevention of paradoxical tuberculosis-associated IRIS
10.1056/nejmc1900116 · 2019 · External reference
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
10.1073/pnas.1007394107 · 2010 · External reference
Opportunistic infections in patients treated with immunotherapy for cancer
10.1186/2051-1426-2-19 · 2014 · External reference
Inflammatory and infectious syndromes associated with cancer immunotherapies
10.1093/cid/ciy1025 · 2019 · External reference
Drug metabolism and variability among patients in drug response
10.1056/nejmra032424 · 2005 · External reference
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
10.1007/s10637-023-01356-5 · 2023 · External reference
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
10.2165/00003088-200544100-00005 · 2005 · External reference
